 |
| venBio's Corey Goodman |
Corey Goodman, the managing partner at venBio, is joining a group of VCs backing Ireland's Heart Metabolics, which is positioning a Phase III-ready heart disease drug for the clinic. VenBio joined Seroba Kernel Life Sciences, Brandon Capital Partners (on behalf of AustralianSuper) and AshHill on the $20 million Series A round, which will provide the cash necessary to buy a portfolio of drugs from the old Heart Metabolics in the U.K. and shift it to the new Dublin-based biotech company. "We are excited to raise the funds necessary from high caliber investors to accelerate the development of perhexiline in a pivotal Phase III clinical trial," said Peter Milner, M.D., CEO of Heart Metabolics Limited and a serial biotech entrepreneur who co-founded CV Therapeutics. "Based on previous clinical data, we believe this drug will be an effective therapy for the rare but deadly heart disease, hypertrophic cardiomyopathy." Release